Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy
- 273 Downloads
Primary liver carcinomas with hepatocellular and cholangiocellular differentiation (b[HB]-PLC) are rare. Surgery offers the best prognosis, but there is a paucity of literature to guide therapy for patients with advanced or unresectable disease. This study aimed to evaluate outcomes of hepatic-directed therapy compared with those of systemic chemotherapy and surgery.
A retrospective evaluation of patients with b(HB)-PLC from 1 January 2008 to 1 September 2014 was conducted. The patients were divided into the following four groups: transplantation (TX) group, surgical resection (SX) group, hepatic directed (HD) group, and systemic chemotherapy alone (SC) group. Overall and progression-free survival, treatment response, and clinicopathologic data were analyzed.
The study included 79 patients (37 females) with an average age of 62 years. The number of patients in each group were as follows: TX group (n = 6), SX group (n = 27), HD group (n = 18), and SC group (n = 28). The mean follow-up periods were 33 months for the TX group, 17 months for the SX group, 14 months for the HD group, and 7 months for the SX group. Overall, 28 % of the patients had cirrhosis and 35 % had viral hepatitis. The candidates for surgery comprised 42 % of the patients. The HD group (n = 18) had a significantly greater objective response than the SC group (n = 28) (47 vs. 6 %; p = 0.02). Two patients who underwent hepatic arterial infusion pump treatment were downstaged to resection. A trend toward improved OS/PFS was observed in the HD group versus the SC group, although statistically significant. The SX group had significantly improved survival (p < 0.001) as did the transplanted patients.
Although surgery offers the best survival for b(HB)-PLC patients, only a minority are candidates for surgery. Because HD therapy showed a superior objective response over SC therapy, it may offer a survival advantage and may downstage patients for surgical resection or transplantation.
KeywordsOverall Survival Gemcitabine Sorafenib Tace Systemic Chemotherapy
The authors acknowledge the support of the Biostastics Core, the Siteman Cancer Center, and NCI Cancer Center Support Grant P30 CA091842.
Conflict of interest
Nael E. Saad is proctor for Sirtex Radiopharamaceuticals.
- 2.Bosman F CF, Hruban R, Theise N. International agency for the research on cancer. In: Bosman FJE, Lakhani S, Ohgaki H editors. Lyon, 2010.Google Scholar
- 4.Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S, et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol. 2013;140:329–40.CrossRefPubMedGoogle Scholar
- 21.Hayashi H, Beppu T, Ishiko T, Mizumoto T, Masuda T, Okabe K, et al. A 42-month disease-free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy. Gan to Kagaku Ryoho Cancer Chemother. 2006;33:1941–3.Google Scholar
- 23.Tani S, Murata S, Tamura M, Fukunaga K, Morita M, Hirata Y, et al. Effectiveness of systemic chemotherapy of GEM+ CBDCA+ 5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases. Nihon Shokakibyo Gakkai Zasshi. 2011;108:1892–901.PubMedGoogle Scholar
- 33.Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, et al. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study. Hepatogastroenterology. 2014;61:162–7.PubMedGoogle Scholar
- 35.Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, et al. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobil Pancreatic Dis Int. 2007;6:161–5.Google Scholar
- 36.Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg. 2006;10:987–98.CrossRefPubMedGoogle Scholar
- 40.Okuda H, Shiratori K, Yamamoto M, Takasaki K, Nakano M. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 2006;21:869–73.CrossRefPubMedGoogle Scholar